Q3 2025 Earnings Summary
- Roivant is actively expanding the indications for brepocitinib (brepo), including initiating a new program in cutaneous sarcoidosis, and is evaluating additional indications, indicating potential for significant growth in their pipeline.
- Roivant made a substantial investment in Immunovant ahead of upcoming data releases, demonstrating strong confidence in their FcRn franchise and the potential for best-in-class therapies like batoclimab and IMVT-1402.
- Upcoming data releases for batoclimab in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) could validate their approach of deeper IgG suppression leading to better clinical outcomes, potentially enhancing the value of their FcRn franchise.
- Uncertain commitment to expanding brepocitinib into new indications: The CEO avoided committing to specific numbers or timelines for rolling out additional indications for brepocitinib, indicating possible delays or cautious progression in the pipeline.
- Cautious tone regarding upcoming batoclimab data: The CEO downplayed the importance of the upcoming MG and CIDP data for batoclimab, suggesting that the results might not be as positive as expected, which could impact the commercial potential of their FcRn franchise. , ,
- Uncertainty in litigation outcomes: The CEO acknowledged that the outcome of the LNP litigation with Moderna and Pfizer/BioNTech is uncertain, with a range of possible outcomes, which could affect future financial results.
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Cash & Marketable Securities | FY 2025 | no prior guidance | $5.2 billion | no prior guidance |
Additional Share Buybacks | FY 2025 | no prior guidance | $500 million | no prior guidance |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Brepocitinib multi-indication expansion | Discussed in Q4 2024 (ongoing pivotal program in dermatomyositis, strong NIU Phase II data) , Q1 2025 (largest DM study, NIU Phase III plans) , Q2 2025 (positioning in DM refractory population, optimism on NIU) | Highlighted as a potential multi-blockbuster franchise in DM, NIU, and cutaneous sarcoidosis; new proof-of-concept study for cutaneous sarcoidosis launched | Consistent topic across periods, with growing emphasis on multi-indication potential |
Anti-FcRn franchise (batoclimab, IMVT-1402) | Featured prominently in Q4 2024 (IMVT-1402 prioritized, potential best-in-class) , Q1 2025 (deep IgG suppression, multiple registrational programs planned) , Q2 2025 (promising data in Graves’, expansion to RA) | Focus on deeper IgG suppression, upcoming 500-patient data, leadership in MG and CIDP; IMVT-1402 highlighted for subcutaneous administration and IP protection | Continues to be a core growth driver; emphasis on upcoming data and broadening indications |
Myasthenia gravis and CIDP data readouts | Q4 2024 discussed top-line MG data expectations in first half of 2025 and CIDP extension , Q1 2025 mentioned MG data early next year and CIDP data shortly thereafter , Q2 2025 briefly mentioned CIDP data next year but not MG | Company expects MG and CIDP data this year, hoping to show that deeper IgG reduction correlates with better clinical outcomes; batoclimab’s 12-week induction for MG and Phase IIb readout in CIDP are key | Partial mention previously; now both MG and CIDP are emphasized together |
Shifting sentiment on batoclimab efficacy | Q4 2024 remained positive on batoclimab, with no indication of lost confidence ; no specific mention in Q1 2025 or Q2 2025 | Discussion of needing a clear dose response in MG to position batoclimab as best-in-class; overall optimism but acknowledging the importance of upcoming data | New detail on potential differentiation; more nuanced focus on establishing best-in-class efficacy |
VTAMA’s performance in psoriasis and AD | Q4 2024 described steady psoriasis revenue ($75M FY) and blockbuster potential in AD , Q1 2025 noted $18.4M quarter, volumes up 20% YoY in psoriasis, enthusiastic about AD launch | No mention in Q3 2025 | No longer discussed in the latest call |
Competition from HUMIRA biosimilars | Mentioned in Q2 2025 as a driver of high HUMIRA failure rates, potentially expanding refractory markets (e.g., DM) | Not mentioned in Q3 2025 | Topic dropped after Q2 |
Namilumab in sarcoidosis | Discussed in Q4 2024 (Phase II data expected, could be first novel therapy) , Q1 2025 (100-patient Phase II, large unmet need) , Q2 2025 (higher-risk but huge opportunity, data by end of quarter) | Not mentioned in Q3 2025 | Reduced focus, no current updates |
Litigation with Moderna and Pfizer/BioNTech | Q4 2024 (favorable Markman ruling vs. Moderna, expert discovery ongoing) , Q1 2025 (discovery phase, trial might be in September 2025) , Q2 2025 (Markman hearing in Pfizer/BioNTech, Moderna case ongoing) | Summary judgment expected in mid-2025, jury trial scheduled for September 2025; court twice declined Moderna’s dismissal attempts, indicating a range of outcomes | Continues to develop, key decisions slated for 2025 |
Strong financial position with litigation risk | Q4 2024 emphasized $6.6B cash, share buyback, capital efficiency , Q1 2025 highlighted net income of $57M, $5.7B in cash , Q2 2025 noted $5.4B in cash, no debt, ongoing LNP litigation | Reported $5.2B in cash and marketable securities, no debt, share buybacks ongoing; trial in Moderna litigation set for September 2025, partial liability possible | Remains strong finances; litigation risk becoming more prominent |
Pipeline catalysts with large opportunities | Q4 2024 pointed to Brepocitinib in NIU, VTAMA in AD, Namilumab in sarcoidosis, Immunovant FcRn as high-value catalysts , Q1 2025 listed Anti-FcRn, Brepocitinib, VTAMA expansion as key near-term events , Q2 2025 noted stacked reads on Namilumab, Brepocitinib, batoclimab | Focused on Brepocitinib expansions (DM, NIU, sarcoidosis), Anti-FcRn in MG/CIDP, and potential financial upside from LNP litigation; management sees path to multi-blockbuster status | Maintained emphasis on near-term data and commercial launches |
-
Upcoming Batoclimab Efficacy Data
Q: What are your expectations for the batoclimab efficacy data?
A: We anticipate seeing a clear dose response between the two doses, which would boost our confidence in achieving best-in-class status. We're also looking across the evidence to optimize our 1402 MG program for maximum success. -
Immunovant Investment Rationale
Q: Why invest in Immunovant now rather than after data, and why not acquire it entirely?
A: We saw an attractive opportunity to invest before the data release, anticipating validation from upcoming results. Owning the entire asset would require significant capital, and issuing large amounts of stock isn't favorable given our current valuation. -
Commitment to Advancing 1402 into MG and CIDP
Q: Will you proceed with 1402 in MG and CIDP regardless of data?
A: We'll assess the data to inform our strategy but remain committed to these large markets with unmet needs. Our unique offerings make us confident in progressing, though the data will shape our approach. -
LNP Litigation Outcomes
Q: What are the possible outcomes of the LNP litigation?
A: There could be a range of outcomes regarding liability between Moderna and the U.S. government. The court has twice declined Moderna's request to use the 1498 defense, signaling potential implications for liability. -
Expanding Brepocitinib Indications
Q: What are your plans for adding more indications for brepocitinib?
A: We are evaluating additional indications that fit our strategic criteria and will reveal them as they are ready. There's a long list of opportunities, and we're choosing spots that leverage our strengths. -
Brepo Phase III Expectations Amid Competition
Q: What are your expectations for brepocitinib's Phase III readout in DM given Argenx's success?
A: We're excited to be the first with a novel mechanism in DM. We believe brepocitinib can deliver meaningful efficacy and possibly be the best overall mechanism among current studies. -
Need for Superior Efficacy Over Competitors
Q: Do you need to show more efficacy than other FcRn players?
A: For commercial success, we don't need to demonstrate superior efficacy. Our molecule's form factor, dosing regimen, and depth of IgG suppression provide advantages even without an efficacy differential.
Research analysts covering Roivant Sciences.